Revolution Medicines (NASDAQ: RVMD) will host an investor webcast on May 31 at 7:00 p.m. ET to discuss results from its Phase 3 RASolute 302 clinical trial. The trial evaluated daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma.

The company described the trial results as positive. The data will be presented during the Plenary Session at the 2026 American Society of Clinical Oncology Annual Meeting before the investor call.

The webcast will be accessible through the company's investor relations website, with a replay available for at least 14 days following the live presentation.

Revolution Medicines develops targeted therapies for patients with RAS-addicted cancers. The company's pipeline includes multiple RAS inhibitors in clinical development, including daraxonrasib, which targets diverse oncogenic variants of RAS proteins.

The information is based on a company press release.